NASDAQ — Healthcare: Manufacturing, Biotechnology: Pharmaceutical Preparations
www.allarity.comAllarity Therapeutics appointed Jesper Høiland as a director, effective June 30, 2025, following the resignation of Joseph W. Vazzano. Høiland will serve on the Audit, Compensation, and Nominating and Corporate Governance Committees. His compensation as an independent director includes a $50,000 annual retainer, with additional fees for committee roles totaling up to $16,500. The new appointment supports Allarity's governance structure as it positions itself for strategic growth within the biotechnology sector, although no immediate financial impacts are disclosed.
Board of Directors AppointmentJoseph W. Vazzano has resigned as a director of Allarity Therapeutics, effective June 30, 2025. The resignation was noted in a Form 8-K filing submitted to the SEC. Following Vazzano’s departure, the Board has appointed Jesper Høiland to fill the vacancy, effective the same date. Høiland will serve as an independent director and will be compensated with a $50,000 annual retainer, plus additional fees for committee memberships. This transition in the boardroom may signal strategic shifts in the company's governance as it approaches its 2026 annual meeting.
Director Resignation